Psoriasis anthralin

Anthralin [1143-38-0] is acetylated using acetyl chloride in toluene and a pyridine catalyst to furnish 1,8-dihydroxy-lO-acetylanthrone [3022-61-5], an intermediate in the preparation of medications used in treating skin disorders, such as warts, psoriasis, and acne (38). Sugar esters can be similarly prepared from acetyl chloride under anhydrous conditions (39). 

Topical therapy is the initial drug treatment strategy for patients with mild to moderate psoriasis. It is estimated that approximately 70% to 80% of all patients with psoriasis can he treated adequately with use of topical therapy.1 Topical therapies include corticosteroids, coal tar products, anthralin, vitamin D3 analogues such as calcipotriol, retinoids such as tazarotene, and topical immunomodulators such as tacrolimus and pime-crolimus.18 Vitamin D3 analogues and topical retinoids all affect keratinocyte functions and the immune response. Currently, these are in wider use than is either anthralin or coal tar preparations. 

UVB light (290 to 320 nm) therapy is an important phototherapeutic intervention for psoriasis. The most effective wavelength is 310 to 315 nm, which led to development of a UVB narrowband light source, in which 83% of the UVB emission is at 310 to 313 nm. Topical and systemic psoriatic therapies are used adj unctively to hasten and improve the response to UVB phototherapy. Emollients enhance efficacy of UVB and can be applied just before treatments. Combining short-contact anthralin, calcipotriene, or topical retinoids to UVB may also improve results. However, topical application should be done after or at least 2 hours before UVB therapy because phototherapy can inactivate the topical product. UVB phototherapy may also be more effective when added to systemic treatments such as methotrexate and oral retinoids. 

Anthralin (Anthra-Derm) is a potent reducing agent whose mechanism of action is unknown. It is approved for the treatment of psoriasis and also may be helpful in alopecia areata. The major toxicides are discoloration of skin, hair, and nails and irritant dermatitis. 

Contraindications Acute psoriasis where inflammation is present, erythroderma, hypersensitivity to anthralin... 

Runne, U., Anthralin-salicylic acid therapy of psoriasis. Cignolin-salicylic acid-vaseline treatment and Lasan paste in a right-left comparison. Hautarzt, 1974, 25 199-200. 

Anthralin Keratolytic Long-term psoriasis Dritho-Calp, Psoriatec 0.5, 1.0... 

Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. / Am Acad Dermatol 1990 23 73-76. 

Anthralin (Anthra-Derm, Lasan) Loosens psoriasis scales can stain skin, clothing, hair, and erythema... 

Anthralin, an anthrone derivative of chrysarobin, was introduced under the name dithranol in Great Britain decades ago. Chronic plaque-type and guttate psoriasis respond better than other variants to anthralin treatment. Topical anthralin, particularly with UV light, is long established as an effective approach to the treatment of psoriasis. ... 

Anthralin, Fig. (18) is the most common therapeutic agent among a small number of pro-oxidant 9-anthrones, effective in the topical treatment of psoriasis. However, the usefulness of this drug is diminished by toxic side effects, including skin irritation and inflammation. Several studies suggest... 

Dithranol (anthralin, cignolin) is a mandatory irritant in psoriasis therapy. Staining of clothes, skin, nails, and hair are frequent and should be explained to patients. An unusual cutaneous anthralin-like staining of the perineum may follow use of danthrone, as a laxative. Danthrone (1,8-dihydroxyanthroquinone) is closely related to dithranol (1,8,9-anthracenetriol). Contact allergy has not been reported. 

---